additionally, examining pharmacogenetic interactions between common genetic variants and nsaid use may allow for more targeted recommendations of nsaids as chemopreventive agents.
Our findings, which partially replicated the results of a previous study, suggest that variants in IκBKβ and NFκB1 are probably associated with CRC risk.